by TractManager | Jul 28, 2021 | News
The Food and Drug Administration (FDA) issued a safety alert for Pepaxto (melphalan flufenamide; Oncopeptides AB) based on results from the OCEAN trial, which demonstrated an increased risk of death.In February 2021, the FDA approved Pepaxto under Accelerated...
by TractManager | Jul 28, 2021 | Emerging Technology Report
Retifanlimab is an investigational intravenous humanized monoclonal antibody that inhibits the activity of programmed death-1 (PD-1). By blocking PD-1, retifanlimab acts as an immune checkpoint inhibitor, freeing T cells to kill cancer cells and boosting immune system...
by TractManager | Jul 21, 2021 | News
On July 16, the Food and Drug Administration (FDA) approved a new indication for Prograf (tacrolimus; Astellas Pharma US Inc.) based on observational study data providing real-world evidence (RWE) of effectiveness. It is the first drug approval based on RWE. The newly...
by TractManager | Jul 15, 2021 | News
The Food and Drug Administration (FDA) issued a safety communication regarding potential mechanical failures and concerns about biocompatibility associated with components of the following NuVasive Specialized Orthopedics MAGEC devices:MAGEC Spinal Bracing and...
by TractManager | Jul 13, 2021 | Health Technology Assessment
Focus of the Report: The use of Zilretta (triamcinolone acetonide extended-release injectable suspension) for the treatment of pain associated with knee osteoarthritis (KOA).Technology Description: Zilretta (Flexion Therapeutics Inc.) is an extended-release...
Recent Comments